T. Rowe Price Investment Management Inc. acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 185,550 shares of the company's stock, valued at approximately $33,455,000. T. Rowe Price Investment Management Inc. owned approximately 0.64% of Krystal Biotech as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Krystal Biotech during the 1st quarter valued at about $74,000. Brooklyn Investment Group lifted its position in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after buying an additional 105 shares in the last quarter. Fox Run Management L.L.C. lifted its position in shares of Krystal Biotech by 8.9% during the 1st quarter. Fox Run Management L.L.C. now owns 2,354 shares of the company's stock valued at $424,000 after buying an additional 193 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Krystal Biotech by 16.8% during the 1st quarter. E Fund Management Co. Ltd. now owns 2,258 shares of the company's stock valued at $407,000 after buying an additional 324 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Krystal Biotech by 8,390.1% during the 1st quarter. Russell Investments Group Ltd. now owns 37,781 shares of the company's stock valued at $6,812,000 after buying an additional 37,336 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Krystal Biotech
In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by insiders.
Krystal Biotech Stock Up 2.1%
NASDAQ KRYS traded up $3.08 during trading on Thursday, hitting $150.72. 165,187 shares of the stock traded hands, compared to its average volume of 328,325. The company has a market capitalization of $4.36 billion, a P/E ratio of 30.61 and a beta of 0.70. The firm has a 50-day simple moving average of $145.15 and a 200-day simple moving average of $154.34. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Guggenheim decreased their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Bank of America decreased their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Citigroup reissued a "neutral" rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Chardan Capital decreased their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $210.38.
Check Out Our Latest Stock Report on Krystal Biotech
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Articles
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access